New Clinical Trial Finds Milestone Scientific’s CompuFlo Instrument a Safe Alternative to Current Standards of Care

Milestone Scientific (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the results of a four hundred patient clinical trial by researchers from the University of Miami, University of Texas and Northwestern University, and two prominent California-based pain clinics.

As quoted in the press release:

Published-Ahead-of-Print in Anesthesia & Analgesia (the official Journal of the International Anesthesia Research Society), the randomized, controlled study compared the effectiveness of the CompuFlo Epidural System (“CompuFlo”) in labor and delivery and chronic pain management, where loss of resistance and fluoroscopy are the current standards of care. CompuFlo was found to be ninety-nine percent successful in objectively identifying the epidural space — even in challenging patients with a higher body mass index.

Performance of epidural anesthesia depends on successful identification of the epidural space. While fluoroscopy is associated with high success, it exposes patients to radiation and requires appropriate radiological equipment. Loss of resistance is subjective and consequently associated with higher failure rates and accidental dural punctures that require further treatment and interventions such as epidural blood patches.

CompuFlo features an innovative Dynamic Pressure Sensing technology^® that differentiates tissue types by pressure signatures at the tip of the needle that are imperceptible by touch. This allows the instrument to accurately identify location and discriminate between true and false loss of resistance objectively and in real-time.

Click here to read the full press release.